Abstract
Extrapulmonary small cell carcinomas (EPSCC) are rare malignancies with poor patient prognoses. We present the case of a 63-year-old male who underwent surgical resection of a poorly differentiated small cell carcinoma, likely from a small intestinal primary tumor that metastasized to the cerebellopontine angle (CPA). A 63-year-old male presented with mild left facial paralysis, hearing loss, and balance instability. MRI revealed a 15 mm mass in the left CPA involving the internal auditory canal consistent with a vestibular schwannoma. Preoperative MRI eight weeks later demonstrated marked enlargement to 35 mm. The patient underwent a suboccipital craniectomy and the mass was grossly different visually and in consistency from a standard vestibular schwannoma. The final pathology revealed a poorly differentiated small cell carcinoma. Postoperative PET scan identified avid uptake in the small intestine suggestive of either a small intestinal primary tumor or additional metastatic disease. The patient underwent whole brain radiation therapy and chemotherapy and at last follow-up demonstrated improvement in his symptoms. Surgical resection and radiotherapy are potential treatment options to improve survival in patients diagnosed with NET brain metastases. We present the first documented case of skull base metastasis of a poorly differentiated small cell carcinoma involving the CPA.
1. Introduction
Poorly differentiated extrapulmonary small cell carcinoma (EPSCC) is a particularly rare subtype of neuroendocrine carcinoma that accounts for 0.1–1.0% of gastrointestinal (GI) tumors. Furthermore, the small intestine represents a rare primary site of EPSCC accounting for 0.2% of all GI malignancies [1–3]. The median age of diagnosis for EPSCC is 70 years with more than 50% of patients presenting with regional lymph node involvement or distant metastasis [3–10]. Multiple case series and single-institution experiences within the literature have attempted to capture the disease course and prognostic factors associated with patients with EPSCC. The median time to progression for patients with limited disease (LD) or extensive disease (ED) is approximately 20 months and 12 months, respectively [11, 12]. The overall survival for patients with EPSCC has been shown to range from 2 to 43 months [11–14]. Despite a dismal prognosis, multimodal therapy improves 2-year survival from 42% to 83% and 5-year survival from 21% to 63% in comparison to local or systemic therapy alone [12].
Brain metastasis is rare and predicts a poor outcome. Overall survival from time of metastasis diagnosis to death varies considerably, from 1 week to 22 months, with some patients showing modest responses to radiotherapy [15–20]. Most patients ultimately present with neurologic symptoms, as well as multiple metastasis to the brain [15–22]. In this paper, we describe the first documented case to the knowledge of the authors of a 63-year-old patient who presented with disturbances of the left 3rd through 8th cranial nerves and underwent surgical resection for skull base metastasis of a poorly differentiated small cell tumor metastasis to the cerebellopontine angle (CPA). We also review the literature on EPSCC with a focus on metastasis to the brain.
2. Case Presentation
A 63-year-old man with a past medical history of hypertension, hyperlipidemia, hypothyroidism, and gout presented with left facial paralysis, dryness and irritation in his left eye, hearing loss, and balance instability that occurred over the course of weeks. The patient was initially diagnosed with benign paroxysmal positional vertigo and started on meclizine with no relief. He was referred to an otolaryngologist and magnetic resonance imaging (MRI) was performed at an outside institution that demonstrated a 15 mm enhancing mass in the left CPA with involvement of the internal auditory canal that was most consistent with a vestibular schwannoma. The patient was counseled as to the different treatment options for a presumed vestibular schwannoma with repeat imaging performed at our institution and chose surgery (Figure 1). Eight weeks later, the patient began experiencing worsening facial function, was classified as a House-Brackmann VI on physical examination, and also reported difficulty with swallowing. A repeat MRI revealed the mass had increased to 35 mm with mass effect on the pons, superior, middle, and inferior cerebellar peduncles with associated edema (Figure 2). The patient subsequently underwent a left-sided retrosigmoid craniotomy. Intraoperatively, the dura and the tumor tissue itself were erythematous, friable, and extremely hemorrhagic. The mass also had an unexpected consistency and appearance as it was very soft, friable, and purplish in color. Preliminary frozen specimens sent to pathology were concerning for lymphoma. The patient’s tumor was then debulked. Post-operatively, the patient underwent a whole body PET scan, which demonstrated high FDG activity in the location of the known residual left CPA mass, as well as an additional hypermetabolic mesenteric lesion abutting the ileum and ascending colon in the right lower quadrant (Figure 2). The final pathology report identified the CPA lesion as a poorly differentiated small cell neuroendocrine carcinoma and was confirmed by positive immunostaining of the tumor cells for cytokeratin CAM 5.2, synaptophysin, and CD56 and a high proliferative index (Figure 3). The tumor cells were negative for CD3, CD20, Epstein-Barr virus, S100, and thyroid transcription factor-1 (TTF-1). The mesenteric lesion was not biopsied at this time. The patient continued to experience symptoms of left facial paralysis, left eye irritation, decreased hearing loss, imbalance, and vertigo postoperatively but was discharged home in good condition. He underwent whole brain radiation therapy followed by chemotherapy and at last follow-up postoperatively has continued to show signs of improvement (Figure 4).
(a)
(b)
(a)
(b)
(c)
(a)
(b)
(a)
(b)
3. Discussion
We present the first documented case of skull base metastasis of EPSCC to the CPA. To date, there have been 24 cases of NET brain metastases in the literature, with 3 patients presenting with carcinoid syndrome, 1 with increasing chromogranin A levels, and 1 diagnosed by radiologic imaging (Table 1) [15–22]. The clinical management of patients presenting with a new lesion revolves around confirmation/localization of the disease, staging, and treatment. Serum chromogranin A levels are elevated in 80% of patients with NET regardless of tumor location and correlate with disease burden. More recently, PET/CT with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) has been used although there is scant evidence investigating the utility of adding this imaging modality for staging to current staging protocols [10, 23, 24]. The role of surgery is complicated in cases of localized and metastatic disease as there is still considerable debate over this issue [1, 7]. Similarly, although GI small cell carcinomas appear to be radiosensitive, cure with radiotherapy is rare; however, concurrent or sequential treatment with chemotherapy may lead to cure or long-term survival in some patients [3, 25–32]. Chemotherapy is shown to induce long-term survival in patients with localized and extended disease with the most commonly used chemotherapeutic drug regimen consisting of cisplatin, etoposide, cyclophosphamide, doxorubicin, and irinotecan [3, 4, 28, 33, 34]. Despite surgical resection and multimodal adjuvant therapy, the prognosis is generally poor [9].
Given our patient’s presentation, no prior history of cancer and initial imaging findings, vestibular schwannoma was at the top of our differential diagnosis. However, given the rapid expansion of the extra-axial mass, we reevaluated our differential, as this was atypical for vestibular schwannomas. Given the mass effect and early hydrocephalus, we elected to proceed with surgical resection, given this treatment modality would allow for diagnosis and debulking of the tumor. Increased serum chromogranin A levels and/or 18-FDG PET scans demonstrating avid uptake in the small intestine performed at an earlier stage would have suggested a different diagnosis of metastatic disease. However, our treatment paradigm would have been the same in both situations with surgical resection, whole brain radiation therapy, and chemotherapy, similar to other reports for brain metastasis in the literature. While a small intestinal primary tumor cannot be definitively shown in this case, the FDG avidity of the mesenteric mass combined with the tumor cells being TTF-1 negative strongly suggests a gastrointestinal primary. While TTF-1 positivity can be seen in both pulmonary and extrapulmonary small cell carcinomas, TTF-1 was not observed in one large series evaluating metastatic neuroendocrine neoplasms of intestinal origin [35, 36].
This case represents the first documented case of skull base metastasis of EPSCC and presented several treatment challenges. The role of chemotherapy versus radiation therapy versus surgical therapy is unclear in patients with skull base metastasis and each is not without its significant risks. The indications for the various treatments may also differ based on site of metastasis; however, this piece of information is currently unknown. Furthermore, the prognosis of patients with skull base metastasis is unclear, which would also help guide treatment options. The metastatic tissue in this case was not amenable to en bloc surgical resection; however, piecemeal surgical resection with subsequent radiation therapy and chemotherapy ultimately achieved improved function.
We present the first documented case of a patient presenting with skull base metastasis to the CPA of GI EPSCC. Similar to Isaka et al. findings, the tumor was found to be highly vascular posing great difficulty in establishing hemostasis [17]. Brain metastasis of EPSCC may be more common than originally thought, as patients may initially present with symptoms related to brain metastasis and not of the primary tumor. Unfortunately, the majority of patients will present with disease not confined to the primary tumor site, leading to poor prognoses. Enhanced imaging modalities and the use of radiotherapy with concurrent or sequential chemotherapy may provide a survival benefit; however, further work is necessary to help define the optimal treatment options for patients with metastatic EPSCC disease to the brain.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.